Deletion of skeletal muscle SOCS3 prevents insulin resistance in obesity

Diabetes

Volumn 62, Issue 1, 2013, Pages 56-64

  Jorgensen, Sebastian Beck ^a,b   O'Neill, Hayley M ^a,c   Sylow, Lykke ^d   Honeyman, Jane ^a   Hewitt, Kimberly A ^a   Palanivel, Rengasamy ^c   Fullerton, Morgan D ^c   Öberg, Lisa ^e   Balendran, Anudharan ^e   Galic, Sandra ^a   Van Der Poel, Chris ^a   Trounce, Ian A ^a   Lynch, Gordon S ^a   Schertzer, Jonathan D ^c   Steinberg, Gregory R ^a,c  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b NOVO NORDISK A S   (Denmark)

^c MCMASTER UNIVERSITY   (Canada)

^d UNIVERSITY OF COPENHAGEN   (Denmark)

^e ASTRAZENECA R AND D   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; INSULIN RECEPTOR SUBSTRATE 1; PROTEIN KINASE B; SUPPRESSOR OF CYTOKINE SIGNALING 3;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APPETITE; ARTICLE; BODY MASS; CONTROLLED STUDY; ENERGY EXPENDITURE; ENZYME PHOSPHORYLATION; FEMALE; GENE DELETION; GLUCOSE INTOLERANCE; GLUCOSE TRANSPORT; HYPERINSULINEMIA; INSULIN RESISTANCE; INSULIN SENSITIVITY; KNOCKOUT MOUSE; LIPID DIET; MALE; MOUSE; MUSCLE DEVELOPMENT; NONHUMAN; OBESITY; PRIORITY JOURNAL; SKELETAL MUSCLE; WILD TYPE;

ANIMALS; INSULIN RECEPTOR SUBSTRATE PROTEINS; INSULIN RESISTANCE; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MUSCLE, SKELETAL; OBESITY; PHOSPHORYLATION; SUPPRESSOR OF CYTOKINE SIGNALING PROTEINS; TRIGLYCERIDES;

EID: 84872045994     PISSN: 00121797     EISSN: 1939327X     Source Type: Journal    
DOI: 10.2337/db12-0443     Document Type: Article

References (47)

1. Galic S, Oakhill JS, Steinberg GR. Adipose tissue as an endocrine organ. Mol Cell Endocrinol 2010;316:129-139
2. Bjørbaek C, Elmquist JK, Frantz JD, Shoelson SE, Flier JS. Identification of SOCS-3 as a potential mediator of central leptin resistance. Mol Cell 1998;1:619-625 (Pubitemid 128374698)
3. Emanuelli B, Peraldi P, Filloux C, et al. SOCS-3 inhibits insulin signaling and is up-regulated in response to tumor necrosis factor-alpha in the adipose tissue of obese mice. J Biol Chem 2001;276:47944-47949
4. Senn JJ, Klover PJ, Nowak IA, et al. Suppressor of cytokine signaling-3 (SOCS-3), a potential mediator of interleukin-6-dependent insulin resistance in hepatocytes. J Biol Chem 2003;278:13740-13746 (Pubitemid 36799910)
5. Ueki K, Kondo T, Kahn CR. Suppressor of cytokine signaling 1 (SOCS-1) and SOCS-3 cause insulin resistance through inhibition of tyrosine phosphorylation of insulin receptor substrate proteins by discrete mechanisms. Mol Cell Biol 2004;24:5434-5446 (Pubitemid 38738176)
6. Steinberg GR, Smith AC, Wormald S, Malenfant P, Collier C, Dyck DJ. Endurance training partially reverses dietary-induced leptin resistance in rodent skeletal muscle. Am J Physiol Endocrinol Metab 2004;286:E57-E63 (Pubitemid 38036610)
7. Rieusset J, Bouzakri K, Chevillotte E, et al. Suppressor of cytokine signaling 3 expression and insulin resistance in skeletal muscle of obese and type 2 diabetic patients. Diabetes 2004;53:2232-2241 (Pubitemid 39145576)
8. Lebrun P, Cognard E, Bellon-Paul R, et al. Constitutive expression of suppressor of cytokine signalling-3 in skeletal muscle leads to reduced mobility and overweight in mice. Diabetologia 2009;52:2201-2212
9. Alexander WS, Hilton DJ. The role of suppressors of cytokine signaling (SOCS) proteins in regulation of the immune response. Annu Rev Immunol 2004;22:503-529 (Pubitemid 38680432)
10. Bjorbak C, Lavery HJ, Bates SH, et al. SOCS3 mediates feedback inhibition of the leptin receptor via Tyr985. J Biol Chem 2000;275:40649-40657 (Pubitemid 32064706)
11. Kievit P, Howard JK, Badman MK, et al. Enhanced leptin sensitivity and improved glucose homeostasis in mice lacking suppressor of cytokine signaling-3 in POMC-expressing cells. Cell Metab 2006;4:123-132 (Pubitemid 44138722)
12. Howard JK, Cave BJ, Oksanen LJ, Tzameli I, Bjørbaek C, Flier JS. Enhanced leptin sensitivity and attenuation of diet-induced obesity in mice with haploinsufficiency of Socs3. Nat Med 2004;10:734-738 (Pubitemid 38937639)
13. Mori H, Hanada R, Hanada T, et al. Socs3 deficiency in the brain elevates leptin sensitivity and confers resistance to diet-induced obesity. Nat Med 2004;10:739-743 (Pubitemid 38937640)
14. Steinberg GR, Dyck DJ. Development of leptin resistance in rat soleus muscle in response to high-fat diets. Am J Physiol Endocrinol Metab 2000;279:E1374-E1382
15. Steinberg GR, Parolin ML, Heigenhauser GJ, Dyck DJ. Leptin increases FA oxidation in lean but not obese human skeletal muscle: evidence of peripheral leptin resistance. Am J Physiol Endocrinol Metab 2002;283:E187-E192 (Pubitemid 34686685)
16. Steinberg GR, Smith AC, Van Denderen BJW, et al. AMP-activated protein kinase is not down-regulated in human skeletal muscle of obese females. J Clin Endocrinol Metab 2004;89:4575-4580 (Pubitemid 39244472)
17. Steinberg GR, McAinch AJ, Chen MB, et al. The suppressor of cytokine signaling 3 inhibits leptin activation of AMP-kinase in cultured skeletal muscle of obese humans. J Clin Endocrinol Metab 2006;91:3592-3597 (Pubitemid 44402142)
18. Minokoshi Y, Kim YB, Peroni OD, et al. Leptin stimulates fatty-acid oxidation by activating AMP-activated protein kinase. Nature 2002;415:339-343 (Pubitemid 34087557)
19. Emanuelli B, Peraldi P, Filloux C, Sawka-Verhelle D, Hilton D, Van Obberghen E. SOCS-3 is an insulin-induced negative regulator of insulin signaling. J Biol Chem 2000;275:15985-15991 (Pubitemid 30366903)
20. Torisu T, Sato N, Yoshiga D, et al. The dual function of hepatic SOCS3 in insulin resistance in vivo. Genes Cells 2007;12:143-154 (Pubitemid 46152654)
21. Sachithanandan N, Fam BC, Fynch S, et al. Liver-specific suppressor of cytokine signaling-3 deletion in mice enhances hepatic insulin sensitivity and lipogenesis resulting in fatty liver and obesity. Hepatology 2010;52:1632-1642
22. Ueki K, Kondo T, Tseng Y-H, Kahn CR. Central role of suppressors of cytokine signaling proteins in hepatic steatosis, insulin resistance, and the metabolic syndrome in the mouse. Proc Natl Acad Sci USA 2004;101:10422-10427 (Pubitemid 38924941)
23. Yaspelkis BB 3rd, Kvasha IA, Figueroa TY. High-fat feeding increases insulin receptor and IRS-1 coimmunoprecipitation with SOCS-3, IKKalpha/beta phosphorylation and decreases PI-3 kinase activity in muscle. Am J Physiol Regul Integr Comp Physiol 2009;296:R1709-R1715
24. Shi H, Cave B, Inouye K, Bjørbaek C, Flier JS. Overexpression of suppressor of cytokine signaling 3 in adipose tissue causes local but not systemic insulin resistance. Diabetes 2006;55:699-707 (Pubitemid 43343226)
25. Kiu H, Greenhalgh CJ, Thaus A, et al. Regulation of multiple cytokine signalling pathways by SOCS3 is independent of SOCS2. Growth Factors 2009;27:384-393
26. Brüning JC, Michael MD, Winnay JN, et al. A muscle-speci fic insulin receptor knockout exhibits features of the metabolic syndrome of NIDDM without altering glucose tolerance. Mol Cell 1998;2:559-569 (Pubitemid 128379082)
27. Galic S, Fullerton MD, Schertzer JD, et al. Hematopoietic AMPK b1 reduces mouse adipose tissue macrophage inflammation and insulin resistance in obesity. J Clin Invest 2011;121:4903-4915
28. O'Neill HM, Maarbjerg SJ, Crane JD, et al. AMPK b1b2 muscle null mice reveal an essential role for AMPK in maintaining mitochondrial content and glucose uptake during exercise. Proc Natl Acad Sci USA 2011;108:16092-16097
29. Martin TL, Alquier T, Asakura K, Furukawa N, Preitner F, Kahn BB. Dietinduced obesity alters AMP kinase activity in hypothalamus and skeletal muscle. J Biol Chem 2006;281:18933-18941 (Pubitemid 44035396)
30. Dzamko N, van Denderen BJ, Hevener AL, et al. AMPK b1 deletion reduces appetite, preventing obesity and hepatic insulin resistance. J Biol Chem 2010;285:115-122
31. Schertzer JD, Gehrig SM, Ryall JG, Lynch GS. Modulation of insulin-like growth factor (IGF)-I and IGF-binding protein interactions enhances skeletal muscle regeneration and ameliorates the dystrophic pathology in mdx mice. Am J Pathol 2007;171:1180-1188 (Pubitemid 47582892)
32. Jørgensen SB, Honeyman J, Oakhill JS, et al. Oligomeric resistin impairs insulin and AICAR-stimulated glucose uptake in mouse skeletal muscle by inhibiting GLUT4 translocation. Am J Physiol Endocrinol Metab 2009;297:E57-E66
33. Saab C, Labiris N, Chirakal R, Farncombe T. A database of normal PET and SPECT radiotracer distributions in rats and mice. J Nucl Med Meeting Abstracts 2007;48:292P-b.
34. Watt MJ, Dzamko N, Thomas WG, et al. CNTF reverses obesity-induced insulin resistance by activating skeletal muscle AMPK. Nat Med 2006;12:541-548
35. Beck Jørgensen S, O'Neill HM, Hewitt K, Kemp BE, Steinberg GR. Reduced AMP-activated protein kinase activity in mouse skeletal muscle does not exacerbate the development of insulin resistance with obesity. Diabetologia 2009;52:2395-2404
36. Trounce IA, Kim YL, Jun AS, Wallace DC. Assessment of mitochondrial oxidative phosphorylation in patient muscle biopsies, lymphoblasts, and transmitochondrial cell lines. Methods Enzymol 1996;264:484-509
37. Spangenburg EE. SOCS-3 induces myoblast differentiation. J Biol Chem 2005;280:10749-10758 (Pubitemid 40395937)
38. Corpeleijn E, Saris WH, Blaak EE. Metabolic flexibility in the development of insulin resistance and type 2 diabetes: effects of lifestyle. Obes Rev 2009;10:178-193
39. Buettner C, Muse ED, Cheng A, et al. Leptin controls adipose tissue lipogenesis via central, STAT3-independent mechanisms. Nat Med 2008;14:667-675 (Pubitemid 351809549)
40. Jørgensen SB, Treebak JT, Viollet B, et al. Role of AMPKalpha2 in basal, training-, and AICAR-induced GLUT4, hexokinase II, and mitochondrial protein expression in mouse muscle. Am J Physiol Endocrinol Metab 2007;292:E331-E339 (Pubitemid 46052958)
41. Winder WW, Holmes BF, Rubink DS, Jensen EB, Chen M, Holloszy JO. Activation of AMP-activated protein kinase increases mitochondrial enzymes in skeletal muscle. J Appl Physiol 2000;88:2219-2226 (Pubitemid 30453931)
42. Li L, Pan R, Li R, et al. Mitochondrial biogenesis and peroxisome proliferator-activated receptor-γ coactivator-1α (PGC-1α) deacetylation by physical activity: intact adipocytokine signaling is required. Diabetes 2011;60:157-167
43. Savage DB, Petersen KF, Shulman GI. Disordered lipid metabolism and the pathogenesis of insulin resistance. Physiol Rev 2007;87:507-520 (Pubitemid 47084679)
44. Iyer A, Fairlie DP, Prins JB, Hammock BD, Brown L. Inflammatory lipid mediators in adipocyte function and obesity. Nat Rev Endocrinol 6:71-82
45. Rui L, Yuan M, Frantz D, Shoelson S, White MF. SOCS-1 and SOCS-3 block insulin signaling by ubiquitin-mediated degradation of IRS1 and IRS2. J Biol Chem 2002;277:42394-42398 (Pubitemid 35257562)
46. Shi H, Tzameli I, Bjørbaek C, Flier JS. Suppressor of cytokine signaling 3 is a physiological regulator of adipocyte insulin signaling. J Biol Chem 2004;279:34733-34740 (Pubitemid 39318104)
47. Tartaglia LA, Dembski M, Weng X, et al. Identification and expression cloning of a leptin receptor, OB-R. Cell 1995;83:1263-1271 (Pubitemid 26007816)